CSPC Innovation Pharmaceutical stock
300765.SZSHZCSPC Innovation Pharmaceutical Co., Ltd., Consumer DefensiveISIN CNE100003K04
36Score 36 out of 100, Weak
Price and trend
51 / 100
Price history
+12% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 1.2% below it.
Since August 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Sharply down: the price has fallen very quickly lately (RSI 28).
The price is 32% below its 52-week high. Largest decline in 8 years: 63% (June 2025 to June 2026).
Chart figures for advanced users
- SMA 50$6.29
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$5.37
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)28
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.48
- The lowest closing price of the last twelve months.
- Resistance$7.77
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- CSPC Innovation Pharmaceutical Co., Ltd. belongs to the Packaged Foods industry (China) and, with a market value of $7.39B, is number 31 of 76 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $322.03M (up 8.4% year on year) and a loss of $36.16M.
- For fiscal 2026, analysts expect on average revenue of $734.17M (up 128%) and adjusted earnings per share of $0.13.
Show more
- MEQIRI Score 36 out of 100 (Weak): rank 288 of 296 in Consumer Defensive, median 62.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $173.59M, financial debt $729.78K.
- Growing faster than its industryRevenue up 10.3% a year since 2020, Packaged Foods median 6.5%.
Weaknesses
- Margin fallingOperating margin −29.1%, average of the prior years 26.3% (to 2024).Profitability 19
- Analysts expect falling earningsDown 22.2% a year through 2028 (estimates from 2 analysts).Growth 30
- Loss-makingLoss of $36.16M over the last 12 months.Fundamentals 49
The score is held back by profitability and capital allocation.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
not measuredNo fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2025, revenue rose 8.4% on the prior year. Revenue has grown solidly since 2014, at about 11% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 32%, operating −29%, net −11%.
Debt & balance sheet
latest quarterDebt is low, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 12 Mar 2027in 119 days
- Last reported
- 29 Oct 2026EPS reported −$0.01
Analyst estimates
- Earnings per share
- $0.13−15.0%
- Revenue
- $734.17M+2.2%
- Earnings per share
- $0.03−22.3%
- Revenue
- $556.1M−2.5%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at CSPC Innovation Pharmaceutical
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
296 rated companies in Consumer Defensive
- This company
- 36
- Sector median
- 62
Categories against the sector medianMedian of 296 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Packaged Foods
The next larger and next smaller companies by market value
- Tingyi (Cayman Islands) Holding0322.HK $9.77B72
- Darling IngredientsDAR $8.74B68
- Lamb Weston HoldingsLW $7.61B59
- Smithfield FoodsSFD $7.47B62
- Meiji Holdings2269.T $7.27B55
- Samyang Foods003230.KS $7.14B76
- Conagra BrandsCAG $6.95B44
- Campbell SoupCPB $6.58B54
ETFs that hold CSPC Innovation Pharmaceutical
Held by 35 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| HSBC MSCI China A UCITS ETF USDH41K | 0.19% | 0.30% | €68.31M |
| Franklin FTSE China UCITS ETFFLXC | 0.02% | 0.19% | €1.43B |
| iShares MSCI China UCITS ETFICGA | 0.02% | 0.28% | €2.21B |
Show 5 more
| UBS MSCI China Universal UCITS ETF USD disUETC | 0.02% | 0.30% | €132.6M |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.01% | 0.17% | €5.24B |
| Amundi MSCI EM Asia ESG Broad Transition UCITS ETF AccLCUA | 0.01% | 0.25% | €661.06M |
| Amundi MSCI Emerging Markets ESG Selection UCITS ETF DR (C)SADM | 0.01% | 0.18% | €1.07B |
| iShares MSCI EM UCITS ETF USD (Dist)IQQE | 0.00% | 0.18% | €8.51B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 May 2025)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.